REGN Regeneron Pharmaceuticals Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
23:44
Apr 09
Apr 09
CNBC
Cramer said Regeneron is "breaking out here," with CEO Leonard Schleifer doing an unbelievable job, and he likes the stock for its pipeline and earnings growth. Company has rising earnings, a strong product pipeline, and positive momentum, making it appealing for investment. Technical breakout and fundamental strength support a LONG position. Pipeline setbacks or regulatory challenges could hinder growth.
REGN
Regeneron Pharmaceuticals
Long
—
—
01:21
Feb 05
Feb 05
CNBC
Diversify into solid earners to survive volatility.
Investors need to diversify away from speculative tech into solid, dividend-paying companies like these to avoid getting smashed by market volatility.
REGN
Regeneron Pharmaceuticals
Long
—
—
00:34
Feb 05
Feb 05
CNBC
Diversify into defensive names like these.
Cramer urges investors to stay diversified, especially if they own speculative assets, and names Kimberly-Clark, Novartis, Regeneron, and FedEx as defensive, less speculative holdings to own. He warns that if volatility persists and investors refuse to diversify into such names, they risk getting smashed.
REGN
Regeneron Pharmaceuticals
Long
1ST
—
—
About REGN Investor Commentary
Across the available history and selected sources, Buzzberg tracks REGN (Regeneron Pharmaceuticals) across 13 sources: 5 bullish vs 0 bearish calls from 19 authors. Historical directional balance: 17% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 30 total trade ideas tracked. Past 7 days, before deduplication: 1 other directions. Latest voices: Jim Cramer.